Loading...
GPCR logo

Structure Therapeutics Inc.NasdaqGM:GPCR Stock Report

Market Cap US$2.7b
Share Price
US$37.19
US$106.47
65.1% undervalued intrinsic discount
1Y69.3%
7D-6.0%
1D
Portfolio Value
​
View

Structure Therapeutics Inc.

NasdaqGM:GPCR Stock Report

Market Cap: US$2.7b

Structure Therapeutics (GPCR) Stock Overview

A clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. More details

GPCR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 58.57% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


GPCR Community Fair Values

Create Narrative

See what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Structure Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Structure Therapeutics
Historical stock prices
Current Share PriceUS$37.19
52 Week HighUS$94.90
52 Week LowUS$15.80
Beta-1.39
1 Month Change-11.89%
3 Month Change-41.09%
1 Year Change69.28%
3 Year Change13.73%
5 Year Changen/a
Change since IPO43.04%

Recent News & Updates

Seeking Alpha • Apr 08

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat

Summary Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior safety and manufacturing cost advantages. GPCR's $1.4B cash position provides runway through 2028 and a valuation floor of $23.10 in a bear scenario. Phase 3 Aleniglipron trial is the key catalyst, with a modeled 67.7% probability of success and potential $6B peak global sales. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Apr 08

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat

Summary Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior safety and manufacturing cost advantages. GPCR's $1.4B cash position provides runway through 2028 and a valuation floor of $23.10 in a bear scenario. Phase 3 Aleniglipron trial is the key catalyst, with a modeled 67.7% probability of success and potential $6B peak global sales. Read the full article on Seeking Alpha
Analysis Article • Jun 24

Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 20

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Summary Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, aleniglipron, an oral GLP-1R agonist, shows potential in obesity treatment with significant Phase 2 data expected in Q4 2025. Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer a competitive edge. With experienced management and multiple upcoming catalysts, Structure could see significant value growth or a potential Big Pharma acquisition. Read the full article on Seeking Alpha
Analysis Article • Mar 11

We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jan 03

Structure Therapeutics: Competitive Data Is Emerging

Summary Structure Therapeutics' GSBR-1290 showed a placebo-adjusted mean weight loss of 6.2% at 12 weeks, suggesting potential despite initial underwhelming results. Comparatively, Eli Lilly’s orforglipron demonstrated superior weight loss, but GSBR-1290's late improvements indicate it might catch up with extended treatment. Financially, Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully realized yet. The weight loss market is projected to reach $200bn by 2029, offering significant prospects for GSBR-1290 despite competitive and developmental risks. Read the full article on Seeking Alpha
Analysis Article • Nov 25

Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Oct 22

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Summary Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024. LTSE-2578 is being developed in phase 1 study targeting patients with idiopathic pulmonary fibrosis; the global idiopathic pulmonary fibrosis market is expected to reach $11.7 billion by 2031. Read the full article on Seeking Alpha
Analysis Article • Aug 11

We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Jun 14

Structure Therapeutics: Yet Another Potential GLP-1 Entrant

Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatment landscape. The company used the spike in the stock to raise additional capital this month. Can Structure compete against Eli Lilly, Novo Nordisk and a host of other potential entrants in an increasingly crowded GLP-1 space? We look at the GLP-1 competitive landscape as well as Structure's prospects in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Jun 05

Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape

Summary Structure Therapeutics Inc.'s oral GLP-1 agonist, GSBR-1290, showed a 6.2% mean weight loss over 12 weeks, significantly outperforming placebo. Adverse events were high, with 89.2% experiencing nausea and 62.2% vomiting. The financial outlook is stable with over three years of cash runway. Hold recommendation for GPCR stock; GSBR-1290 has potential, but competition and adverse effects warrant caution. Read the full article on Seeking Alpha
Analysis Article • Mar 10

Here's Why We're Not Too Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 29

Structure Therapeutics (NASDAQ:GPCR) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

GPCRUS PharmaceuticalsUS Market
7D-6.0%-2.0%1.2%
1Y69.3%36.2%27.0%

Return vs Industry: GPCR exceeded the US Pharmaceuticals industry which returned 40.5% over the past year.

Return vs Market: GPCR exceeded the US Market which returned 28.2% over the past year.

Price Volatility

Is GPCR's price volatile compared to industry and market?
GPCR volatility
GPCR Average Weekly Movement7.7%
Pharmaceuticals Industry Average Movement10.0%
Market Average Movement7.2%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: GPCR has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: GPCR's weekly volatility has decreased from 17% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016220Raymond Stevensstructuretx.com

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis.

Structure Therapeutics Inc. Fundamentals Summary

How do Structure Therapeutics's earnings and revenue compare to its market cap?
GPCR fundamental statistics
Market capUS$2.74b
Earnings (TTM)-US$141.20m
Revenue (TTM)n/a
0.0x
P/S Ratio
-18.7x
P/E Ratio

Is GPCR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GPCR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$141.20m
Earnings-US$141.20m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.99
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GPCR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/02 10:56
End of Day Share Price 2026/06/02 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Structure Therapeutics Inc. is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Evan SeigermanBMO Capital Markets Equity Research
Edward NashCanaccord Genuity
Prakhar AgrawalCantor Fitzgerald & Co.